Now Reading: Dr Reddy’s terminates distribution pact with Novartis India
-
01
Dr Reddy’s terminates distribution pact with Novartis India
Drugmaker Dr Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India, citing a change in the Swiss firm's controlling shareholding. The pact, signed in February 2022, will end by…
The Story in Brief
Drugmaker Dr Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India, citing a change in the Swiss firm's controlling shareholding. The pact, signed in February 2022, will end by September 30, 2026, Dr Reddy's said in a stock exchange filing on August 10. Novartis India confirmed the termination agreement was executed on August 7 and will regain exclusivity and market access for the affected products.
The termination follows private equity firm ChrysCapital's acquisition of a controlling 70.68% stake in Novartis India, announced on July 29. This is ChrysCapital's first majority-controlled investment in Indian pharma. Novartis India's key brands include painkiller Voveran, calcium supplement Calcium Sandoz, and anti-epilepsy drug Tegrital, covering areas like gynaecology and transplant immunology.
The Indian Opinion
Some may see this termination as a setback for Novartis India after ChrysCapital's acquisition. However, the facts suggest a planned transition rather than a fallout. The six-month notice period and existing profit-sharing indicate an orderly separation. The real test will be whether Novartis India can rebuild its own distribution network and maintain market share for brands like Voveran without Dr Reddy's help. Does this signal a broader trend of drugmakers bringing sales in-house, or is it just a one-off corporate realignment?
Source: thehindu.com
This story was synthesised by AI from the source linked above.
